ANAlvand Naserghandi

Alvand Naserghandi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alvand Naserghandi has a total of 34 co-authors. Here are the top co-authors by number of shared publications:

  • Mohammad Amin Tofighi Zavareh

    Student Research Committee, Shahid Beheshti University of Medical Sciences, Tehran, Iran

    2 shared publications
  • Abdol-Mohammad Kajbafzadeh

    Pediatric Urology and Regenerative Medicine Research Center, Gene, Cell and Tissue Research Institute, Children's Medical Center Tehran University of Medical Sciences Tehran Iran

    1 shared publication
  • Alireza Ghahremani

    Nano Bio Electronic Devices Lab, Nano Electronic Center of Excellence, School of Electrical and Computer Engineering, College of Engineering, University of Tehran, Tehran, Iran

    1 shared publication
  • Amir Reza Abedi

    Men’s Health and Reproductive Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

    1 shared publication
  • Arash Hassanpour Dargah

    Pediatric Urology and Regenerative Medicine Research Center, Gene, Cell and Tissue Research Institute, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran

    1 shared publication
  • Atena Tamimi

    Student Research Committee, Shahid Beheshti University of Medical Sciences School of Medicine, Tehran, Iran

    1 shared publication

Latest Publications

  • Can inter-sphincteric and pelvic floor botulinum toxin type A injections enhance clinical outcomes in pediatric patients with non-neurogenic dysfunctional voiding?

    by Pooya Hekmati, Negar Mohammadi Ganjaroudi, Arash Hassanpour Dargah, Mahdiyar Jaberi, Mohammad Amin Siri, Alvand Naserghandi, Soroush Mozafari, Abdol-Mohammad Kajbafzadeh


  • Open Access

    Management challenges in renal arteriovenous malformation mimicking AVF/pseudoaneurysm without trauma or pathological cause

    by Farzad Allameh, Niki Tadayon, Mohammad Amin Tofighi Zavareh, Seyed Mohammad SadrAmeli, Alvand Naserghandi

  • Open Access

    Prostate Cancer and the Rise of Focal Laser Therapies: A Narrative Review of Benefits and Limitations

    by Alvand Naserghandi, Amir Reza Abedi, Mohammad Amin Tofighi Zavareh, Mohammad Javad Shahsavari, Mohammad Mehdi Shadravan, Soroush Mirzaei, Mohamad Amir Kakaee, Farzad Allameh

    Introduction: Prostate cancer is the second most prevalent cancer in men and remains a major global health concern. Traditional treatment modalities such as radical prostatectomy (RP) and radiation therapy, while effective, often result in significant morbidity, including urinary incontinence and sexual dysfunction. Methods: A narrative review was conducted to synthesize current evidence on focal laser therapy for prostate cancer. A comprehensive literature search was performed across three major databases: PubMed, Scopus, and Web of Science. The search strategy employed the following Medical Subject Headings (MeSH) terms and keywords: ("Prostatic Neoplasms" [MeSH] OR "prostate cancer") AND ("Laser Therapy" [MeSH] OR "laser ablation" OR "focal therapy"). The search was limited to studies published between 2000 and 2024. Results: The initial search retrieved 1,444 articles. After a rigorous screening of titles, abstracts, and full-texts, 79 studies met the inclusion criteria and were incorporated into the review. The selected literature enables a comprehensive and critical evaluation of the current state of research on focal laser therapy in the management of prostate cancer. Conclusion: While focal laser therapies offer promising outcomes with fewer side effects, their long-term efficacy and survival benefits remain uncertain. High-quality studies with long-term follow-up are essential to better define their role in the prostate cancer treatment landscape and inform optimal patient selection.


  • Intra Operative Mild Cooling of Large Tumors Reduces Their Invasive and Metastatic Functions While Increasing Their Resistance to Apoptosis

    by Noureddin Tavassoli, Alireza Ghahremani, Kosar Namakin, Alvand Naserghandi, Seyed Rouhollah Miri, Mohammad Abdolahad

    Cancer treatment often involves excisional surgery, but this approach may leave behind minimal residual disease, leading to tumor regrowth. Proinflammatory cytokines and their role in altering residual cancerous cells postsurgery have garnered attention. The study examines how mild intraoperative cooling affects cancer cells and their gene expression. It aims to discover strategies for reducing tumor growth after surgery. Nine cases of solid tumor were included in the study, nine samples were cooled with the Peltier–Seebeck device down to12°C, and cooled and noncooled regions of tumors were analyzed using reverse transcription-polymerase chain reaction. Key transcriptomes, including neural-cadherin, cadherins ( CDH ), 70-kDa Heat Shock Protein ( HSP70 ), hypoxia-inducible factor ( HIF ), Y-Box-binding protein 1 ( YB-1 ), matrix metalloproteinase 9 ( MMP9 ), and matrix metalloproteinase 2 ( MMP2 ), were measured to assess the impact of mild hypothermia on cancer cell metabolism and cold shock responses. Analysis of cooled and noncooled regions revealed reduced MMP2/9 levels in cooled regions in five out of seven cases, indicating potential suppression of tumor invasion and metastasis. CDH-1 expression was detected in five cases, with decreased levels observed in cooled regions in most cases, suggesting a role in tumor aggressiveness. YB-1 expression was increased in six out of eight samples, possibly correlating with local recurrence and reduced overall survival times. N-Cad expression was increased in all five samples where it was detected, indicating its potential involvement in tumor cell motility and invasion. HSPs showed a mild increase in four out of five cases following cooling, potentially contributing to tumor cell resistance to cooling-induced apoptosis. Intraoperative mild cooling resulted in the downregulation of key proteins playing a role in invasion and metastasis. However, Elevated YB-1 and N-Cad expression limits cooling's universal application. Further research is necessary to comprehend cooling-related transcriptome changes and their impact on patient outcomes.

  • Open Access

    Omicron variant of COVID-19: A focused review of biologic, clinical, and epidemiological changes

    by Hossein Majlesi, Saba Shahsavan, Yeganeh Farsi, Atena Tamimi, Saba Ilkhani, Zohreh Tajabadi, Alvand Naserghandi, Niloofar Fakour, Mohammad Javad Nasiri, Ehsan Nazemallhoseini-Mojarad, et al.

    On 25 November 2021, the world health organization listed Omicron as a newly arisen and the fifth variant of concern (VoC) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The genome sequence of Omicron showed the utmost number of mutations compared to other known VoCs up to now, and it was regarded as the only SARS-CoV-2 variant with changes in the receptor-binding domain (RBD). However, the Omicron is still detectable via previous polymerase chain reaction (PCR) tests. Clinical presentation of the disease is identical to previous VoCs, however in vitro and in vivo studies revealed a higher transmission rate. The biggest obstacles posed by Omicron are the immune escape and reduction in vaccine effectiveness, as indicated by many simulations and real-world studies. Although the efficacy of the two-dose vaccinations is suboptimal for Omicron, preliminary studies have considered the injection of a booster shot is beneficial and can decrease the risk of severe disease. All these new features of Omicron warranted close investigation of this VoC as a new chapter in the pandemic, especially with emersion of subvariants BA.4 and BA.5. This review presents a conspectus of the current knowledge on the COVID-19 Omicron variant biological, clinical, and epidemiological changes.


  • Open Access

    All about COVID-19 in brief

    by A. Naserghandi, S.F. Allameh, R. Saffarpour